MM-459 Safety and Clinical Activity of Belantamab Mafodotin With Lenalidomide Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-6 Arm-A Interim Analysis

Autor: Quach, Hang 1, Gironella, Mercedes 2, Lee, Cindy 3, Popat, Rakesh 4, Cannell, Paul 5, Kasinathan, Ravi S. 6, Chopra, Bikramjit 7, Rogers, Rachel 6, Ferron-Brady, Geraldine 6, Shafi-Harji, Seema 8, Patel, Nashita 7, Opalinska, Joanna 6, Gupta, Ira 6, Augustson, Bradley 9
Zdroj: In Clinical Lymphoma, Myeloma and Leukemia October 2022 22 Supplement 2:S423-S424
Databáze: ScienceDirect
Externí odkaz: